Predicted Trait | |
Reported Trait | Vitiligo |
Mapped Trait(s) | Vitiligo (EFO_0004208) |
Score Construction | |
PGS Name | VIT |
Development Method | |
Name | GCTA-COJO forward selection highest PPA variants |
Parameters | p < 5e-8, +/-500kb window, 10K EUR UKB individuals as LD reference, MHC region removed |
Variants | |
Original Genome Build | hg19 |
Number of Variants | 42 |
Effect Weight Type | beta |
PGS Source | |
PGS Catalog Publication (PGP) ID | PGP000164 |
Citation (link to publication) | Khan Z et al. Nat Commun (2021) |
Study Identifiers | Sample Numbers | Sample Ancestry | Cohort(s) |
---|---|---|---|
GWAS Catalog: GCST004785 Europe PMC: 27723757 |
40,258 individuals | European | NR |
Study Identifiers | Sample Numbers | Sample Ancestry | Cohort(s) | Phenotype Definitions & Methods | Age of Study Participants | Participant Follow-up Time | Additional Ancestry Description | Additional Sample/Cohort Information |
---|---|---|---|---|---|---|---|---|
— | [
|
European | UKB | ICD9 244 and self-reported hypothyroidism | — | — | — | Source GWAS summary statistics without MHC https://my.locuszoom.org/gwas/552910/ |
PGS Performance Metric ID (PPM) |
PGS Sample Set ID (PSS) |
Performance Source | Trait |
PGS Effect Sizes (per SD change) |
Classification Metrics | Other Metrics | Covariates Included in the Model |
PGS Performance: Other Relevant Information |
---|---|---|---|---|---|---|---|---|
PPM001935 | PSS000970| European Ancestry| 1,584 individuals |
PGP000164 | Khan Z et al. Nat Commun (2021) |
Reported Trait: anti-PD-L1 induced hypothyroidism in cancer patients | HR: 1.41 [1.22, 1.61] | — | meta-analysis p-value: 1.10e-06 | 5 genotype PCs | — |
PGS Sample Set ID (PSS) |
Phenotype Definitions and Methods | Participant Follow-up Time | Sample Numbers | Age of Study Participants | Sample Ancestry | Additional Ancestry Description | Cohort(s) | Additional Sample/Cohort Information |
---|---|---|---|---|---|---|---|---|
PSS000970 | — | Median = 400.0 days | 1,584 individuals | — | European | — | GNEHGI2020Q2 | — |